secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-08-10T12:00:30+00:00
Accession:  0001493152-26-036742
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir publishes peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in TNBC and prostate models
--------------------------------------------------------------------------------

- Telomir-Zn inhibits KDM histone demethylases by depleting intracellular iron; iron-rescue experiments confirmed mechanism specificity in TNBC cells.
- In HCC1806 TNBC xenografts, Telomir-Zn significantly reduced metastatic dissemination; combined with paclitaxel in BT-549 models showed synergistic tumor reduction.
- In prostate cancer model, oral Telomir-Zn reactivated silenced tumor-suppressor genes STAT1, GSTP1, RASSF1A, CDKN2A, and MASPIN.
- Selective killing: TNBC cancer cells killed at low concentrations while normal cells unharmed at >50-fold higher concentrations; MDA-MB-231 xenografts did not respond.
- Data supports planned Phase 1/2 TNBC trial under active FDA IND; CEO Erez Aminov cites limited options for advanced TNBC patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226036742/0001493152-26-036742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226036742/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer